N-Terminal-Pro Brain Natriuretic Peptide (NT-pro BNP) and Troponin I as prognostic markers of septic cardiomyopathy
Authors:
Stachura Peter 1; Turek Zdeněk 2; Švábl Miroslav 1; F. Hausmann Dieter 1
Authors place of work:
Klinik für Anästhesiologie und operative Intensivmedizin, Klinikum Bayreuth GmbH, Deutschland
1; KARIM UK v Praze, LF v Hradci Králové a FN Hradec Králové
2
Published in the journal:
Anest. intenziv. Med., 24, 2013, č. 3, s. 169-178
Category:
Intenzivní medicína - Původní práce
Summary
Objective:
Cardiac dysfunction might be a considerable factor determining the outcome of critically ill patients. NT-pro BNP is highly predictive for the functional and troponin I for the morphological heart dysfunction in septic, critically ill patients. We compared the sensitivity and specificity of NT-pro BNP and troponin I in septic patients to the outcome markers SOFA score and procalcitonin.
Design:
Prospective, observational trial.
Setting:
Surgical Intensive Care Unit (SICU) at a tertiary care hospital.
Materials and Methods:
The trial criteria were met by 16 survivors and 17 non-survivors with severe sepsis or septic shock. ROC curves analysis was made for seven consecutive days of severe sepsis.
Results:
NT-pro BNP was a significantly better prognostic parameter than other parameters (AUC on day 3 = 0.850, cut-off value ≤ 3910 pg/ml) from the third day of severe sepsis. The highest AUC of NT-pro BNP was measured on day 4 (AUC = 0.878) with sensitivity of 100.0% (95% CI 66.4–100.0) and specificity of 80.0% (95% CI 44.4–97.5) by cut-off value ≤ 5 473 pg/ml. Troponin I showed insufficient results in the first two days of severe sepsis with continuous improvement in the next five observed days. The highest AUC was measured on day 4 (AUC = 0.811). The sensitivity of the best cut-off value of troponin I(≤ 0.1 ng/ml) on day 4 was 100.0% (95% CI 66.4–100.0) and specificity 70% (95% CI 34.8–93.3). Procalcitonin was significant at the beginning of severe sepsis only. The best AUC for procalcitonin was measured on day 1 (0.761). SOFA score correlated with the outcome of critically ill septic patients from day 3 and reached the best values on day 6 (AUC = 0.795).
Conclusions:
NT-pro BNP values higher than 3910 pg/mland positive troponin I values in septic patients over 65 years taken on day 3 could be an early marker of risk in patients with myocardial dysfunction. Continuously rising values of NT-pro BNP and higher levels of troponin I during severe sepsis are helpful prognostic markers, superior to other predictors of outcome. Rising values of NT-proBNP and troponin I need diagnostic precision and targeted therapy of septic myocardial dysfunction.
Keywords:
natriuretic peptides – cardiac troponins – septic cardiomyopathy – diagnosis – prognosis
Zdroje
1. Almog, Y. et al. Plasma level of N terminal pro-brain natriuretic peptide as a prognostic marker in critically ill patients. Anesth. Analg., 2006, 102, p. 1809–1815.
2. Müller-Werdan, U. et al. Septische Kardiomyopathie. Intensivmed, 2006, 43, p. 486–497.
3. Uchino, S. et al. Pulmonary artery catheter versus pulse contour analysis: a prospective epidemiological study. Crit. Care, 2006, p. R174.
4. Maeder, M. Sepsis-Associated Myocardial Dysfunction: Diagnostic and Prognostic Impact of Cardiac Troponins and Natriuretic Peptides. Chest, 2006, 129, p. 1349–1366.
5. Charpentier, J. et al. Brain natriuretic peptide: A marker of myocardial dysfunction and prognosis during severe sepsis. Crit. Care Med., 2004, 32, p. 660–665.
6. Nielsen, L. N-terminal pro-brain natriuretic peptide for discriminating between cardiac and non-cardiac dyspnoea. European Journal of Heart Failure, 2004, 6, p. 63–70.
7. Dellinger, R. P. et al. Surviving Sepsis Campaign: International guidelines for management of severe sepsis and septic shock: 2008. Intens. Care Med., 2008, 34, p. 17–60.
8. Bouch, D. C., Thompson, J. P. Severity scoring systems in the critically ill. Continuing Education in Anaesthesia, Crit. Care & Pain, 2008, 8, p. 181–185.
9. Minne, L., Abu-Hanna, A., Jonge, E. de Evaluation of SOFA-based models for predicting mortality in the ICU: A systematic review. Crit. Care, 2009, 12, p. R161.
10. Higgins, T. L. et al. Assessing contemporary intensive care unit outcome: An updated Mortality Probability Admission Model (MPM0-III)*. Crit. Care Med., 2007, 35, p. 827–835.
11. Khwannimit, B., Bhurayanontachai, R. The performance of customised APACHE II and SAPS II in predicting mortality of mixed critically ill patients in a Thai medical intensive care unit. Anaesth. Intensive Care, 2009, 37, p. 784–790.
12. Galrinho, A. et al. Prognostic implications of tissue Doppler in patients with dilated cardiomyopathy. Rev. Port. Cardiol., 2006, 25, p. 781–793.
13. Landesberg, G. et al. Diastolic dysfunction and mortality in severe sepsis and septic shock. Eur. Heart J., 2012, 33, p. 895–903.
14. Sturgess, D. J. et al. Prediction of hospital outcome in septic shock: a prospective comparison of tissue Doppler and cardiac biomarkers. Crit. Care, 2010, 14, p. R44.
15. Sakka, S. et al. Prognostic value of extravascular lung water in critically ill patients. Chest, 2002, 122, p. 2080–2086.
16. Phillips, C., Chesnutt, M., Smith, S. Extravascular lung water in sepsis-associated acute respiratory distress syndrome: indexing with predicted body weight improves correlation with severity of illness and survival. Crit. Care Med., 2008, 36, p. 69–73.
17. Røsjø, H. et al. Circulating high sensitivity troponin T in severe sepsis and septic shock: distribution, associated factors, and relation to outcome. Intens. Care Med., 2011, 37, p. 77–85.
18. Liu, D. et al. Prognostic value of plasma N-terminal pro-B-type natriuretic peptide in patients with severe sepsis and septic shock. Sichuan Da Xue Xue Bao Yi Xue Ban, 2011, 42, p. 369–373.
19. Park, B. et al. Prognostic utility of changes in N-terminal pro--brain natriuretic Peptide combined with sequential organ failure assessment scores in patients with acute lung injury/acute respiratory distress syndrome concomitant with septic shock. Shock, 2011, 36, p. 109–114.
20. Cuthbertson, B. H. et al. B-Type natriuretic peptide and the prediction of outcome in patients admitted to intensive care. Anaesthesia, 2005, 60, p. 16–21.
21. Park, M. S. et al. Prognostic utility of changes in N-terminal pro-brain natriuretic Peptide combined with sequential organ failure assessment scores in patients with acute lung injury/acute respiratory distress syndrome concomitant with septic shock. Shock Augusta Ga, 2010, 36, p. 109–114.
22. Banach, M. et al. NT-proBNP levels correlate with organ failure in septic patients: a preliminary report. Postepy higieny i medycyny doswiadczalnej Online, 2006, 60, p. 632–636.
23. Levy, M. M. et al. The Surviving Sepsis Campaign: results of an international guideline-based performance improvement program targeting severe sepsis. Intens. Care Med., 2010, 36, p. 222–231.
24. Vaitsis, J. et al. Use of levosimendan in myocardial dysfunc-tion due to sepsis. Crit. Care, 2009, 13, p. P165.
25. Morelli, A. et al. Effects of levosimendan on systemic and regional hemodynamics in septic myocardial depression. Intensive Care Med., 2005, 31, p. 638–644.
26. Tavener, S. A. et al. Immune cell Toll-like receptor 4 is re-quired for cardiac myocyte impairment during endotoxemia. Circ. Res., 2004, 95, p. 700–707.
27. Leon, C. G. et al. Discovery and Development of Toll-Like Receptor 4 (TLR4) Antagonists: A New Paradigm for Treating Sepsis and Other Diseases. Pharm Res., 2008, 25, p. 1751–1761.
28. Mokart, D. et al. N-terminal pro-brain natriuretic peptide as an early prognostic factor in cancer patients developing septic shock. Critical Care, 2007, 11, p. R37
29. Van Kimmenade, R. R. et al. Renal clearance of B-type natriuretic peptide and amino terminal pro-B-type natriuretic peptide a mechanistic study in hypertensive subjects. J. Am. Coll. Cardiol., 2009, 53, p. 884–890.
30. Raymond, I. et al. The influence of age, sex and other varia-bles on the plasma level of N-terminal pro brain natriuretic peptide in a large sample of the general population. Heart, 2003, 89, p. 745–775.
31. Flierl, M. et al. Molecular events in the cardiomyopathy of sepsis. Molecular Medicine, 2008, 14, p. 327–336.
32. Romero-Bermejo, F. J. et al. Sepsis-induced Cardiomyopathy. Current Cardiology Reviews, 2011, 7, p. 163–183.
Štítky
Anestéziológia a resuscitácia Intenzívna medicínaČlánok vyšiel v časopise
Anesteziologie a intenzivní medicína
2013 Číslo 3
- Vliv komorbidit na účinnost ceftarolin-fosamilu u komplikovaných infekcí kůže a měkkých tkání − sdružená analýza 3 studií
- e-Konzilium.cz — Masivní plicní embolie při tromboembolické nemoci
- Kvalita výživy na JIS a následná kvalita života spolu úzko súvisia
- DESATORO PRE PRAX: Aktuálne odporúčanie ESPEN pre nutričný manažment u pacientov s COVID-19
Najčítanejšie v tomto čísle
- Anesteziologický přístroj,dýchací systémy
- Klinická fyziologie koronární cirkulace
- NT-pro BNP a troponín I ako prognostické parametre septickej kardiomyopatie
- Desfluran – neprávem Popelkou